INTRODUCTION
The growth of renal transplantation in the past decade and the increased amount of clinical experience in this area has allowed many transplant centres to broaden their criteria for patient selection. This has resulted in the acceptance of many patients, who were formerly considered as being 'non-ideal', into renal transplant programmes. While individual risk factors such as diabetes mellitus, cardiovascular disease, hypertension, age and race have been pointed out,1 9 no standardised system has been employed to evaluate the contributions of the various risk factors to renal transplant outcome and patient survival. At our centre, we have considered the combined effects of the multiple risk factors that are often simultaneously present in these patients prior to transplantation.10 This has led to development of a scale for comparison of individual risk factors (Table 1) first 24 hours after transplantation, an oral dose of 4 -5 mg/kg was administered on post-operative days 1 -3, and 6 -8 mg/kg on days 4 -5. The serum cyclosporin A levels were determined on days 4 and 5, and the dose was then adjusted to maintain serum levels between 100 and 200 mg/ml. After two months the dose was fixed at 4-5 mg/kg daily regardless of serum levels. Prednisolone 1 mg/kg was given immediately prior to transplant. No prednisolone was given during the first 24 hours post-operatively. Patients received prednisolone at a dosage of 1 mg/kg on day 2, 0.75 mg/kg on days 3-5, 0.5 mg/kg on days 5 -7, and were maintained at this level until discharge. Within two weeks posttransplantation, prednisolone was tapered to 20 mg daily and decreased to 5-7.5 mg daily within 3 months after transplant. Some patients were later completely removed from prednisolone. Rejection was treated with methylprednisolone sodium succinate, 250 mg administered intravenously every 8-12 hours for 3 days. Occasionally, antilymphocytic globulin was used to treat rejection when no response to methylprednisolone was obtained.
ANALYSIS OF RISK
Each patient in Groups I and 11 was evaluated to determine his or her cumulative risk prior to transplantation. Each individual risk factor was weighted as in Table I and a final risk index was calculated by adding these together. Patients with a risk index < .6 were considered to be good risk candidates for transplantation. Risk indices .6 < x < .9 were considered to be at high risk. The very high risk category included cumulative indices in the .9 < x < 1.1 range. Extremely high risk was indicated by indices > 1.1. It is apparent that a well developed system for determining the risk to life as part of the pre-transplant evaluation would be useful for decision-making both before and after transplantation. Accurate determinations of this risk could be used to individualise immunosuppressive therapy and would assist decisions regarding pursuit of re-transplantation after a graft has been lost to rejection. The results obtained from application of our risk categorisation system to cyclosporin A treated renal transplant recipients was affected by an overall reduction in patient mortality as compared with the previous antilymphocytic globulin treated group. Although our patient populations are small in both groups, this improvement in survival may be due to the steroid-sparing effect of cyclosporin A administration.
RESULTS
Major risk factors such as cardiac disease and hypertension will cause fatal complications late in the course of the transplants, which will further influence survival.
We encourage other centres to utilise our system for risk categorisation or to modify it to accommodate the risk factors which may be additionally present in their patient population. In this way, risk categorisation may become an integral part of the pre-transplant patient evaluation and can be used to predict outcome after renal transplantation.
